284 related articles for article (PubMed ID: 26212366)
1. Discovery of Novel Peptidomimetics as Irreversible CHIKV NsP2 Protease Inhibitors Using Quantum Mechanical-Based Ligand Descriptors.
El-labbad EM; Ismail MA; Abou Ei Ella DA; Ahmed M; Wang F; Barakat KH; Abouzid KA
Chem Biol Drug Des; 2015 Dec; 86(6):1518-27. PubMed ID: 26212366
[TBL] [Abstract][Full Text] [Related]
2. Conformer and pharmacophore based identification of peptidomimetic inhibitors of chikungunya virus nsP2 protease.
Dhindwal S; Kesari P; Singh H; Kumar P; Tomar S
J Biomol Struct Dyn; 2017 Dec; 35(16):3522-3539. PubMed ID: 27844505
[TBL] [Abstract][Full Text] [Related]
3. Design and Validation of Novel Chikungunya Virus Protease Inhibitors.
Das PK; Puusepp L; Varghese FS; Utt A; Ahola T; Kananovich DG; Lopp M; Merits A; Karelson M
Antimicrob Agents Chemother; 2016 Dec; 60(12):7382-7395. PubMed ID: 27736770
[TBL] [Abstract][Full Text] [Related]
4. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.
Jadav SS; Sinha BN; Hilgenfeld R; Jayaprakash V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):346-361. PubMed ID: 28294048
[TBL] [Abstract][Full Text] [Related]
5. Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease.
Singh H; Mudgal R; Narwal M; Kaur R; Singh VA; Malik A; Chaudhary M; Tomar S
Biochimie; 2018 Jun; 149():51-61. PubMed ID: 29635044
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidone derivatives as inhibitors of chikungunya virus.
Jadav SS; Sinha BN; Hilgenfeld R; Pastorino B; de Lamballerie X; Jayaprakash V
Eur J Med Chem; 2015 Jan; 89():172-8. PubMed ID: 25462237
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus.
Bassetto M; De Burghgraeve T; Delang L; Massarotti A; Coluccia A; Zonta N; Gatti V; Colombano G; Sorba G; Silvestri R; Tron GC; Neyts J; Leyssen P; Brancale A
Antiviral Res; 2013 Apr; 98(1):12-8. PubMed ID: 23380636
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, antiviral evaluation, and In silico studies of acrylamides targeting nsP2 from Chikungunya virus.
Souza BG; Choudhary S; Vilela GG; Passos GFS; Costa CACB; Freitas JD; Coelho GL; Brandão JA; Anderson L; Bassi ÊJ; Araújo-Júnior JX; Tomar S; Silva-Júnior EFD
Eur J Med Chem; 2023 Oct; 258():115572. PubMed ID: 37364511
[TBL] [Abstract][Full Text] [Related]
9. Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Aug; 37(12):3150-3161. PubMed ID: 30114965
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication.
Di Mola A; Peduto A; La Gatta A; Delang L; Pastorino B; Neyts J; Leyssen P; de Rosa M; Filosa R
Bioorg Med Chem; 2014 Nov; 22(21):6014-25. PubMed ID: 25282648
[TBL] [Abstract][Full Text] [Related]
12. Identification of chikungunya virus nsP2 protease inhibitors using structure-base approaches.
Nguyen PT; Yu H; Keller PA
J Mol Graph Model; 2015 Apr; 57():1-8. PubMed ID: 25622129
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya virus infections: time to act, time to treat.
Abdelnabi R; Neyts J; Delang L
Curr Opin Virol; 2017 Jun; 24():25-30. PubMed ID: 28414993
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of chikungunya virus nsP2 cysteine protease reveals a putative flexible loop blocking its active site.
Narwal M; Singh H; Pratap S; Malik A; Kuhn RJ; Kumar P; Tomar S
Int J Biol Macromol; 2018 Sep; 116():451-462. PubMed ID: 29730006
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.
Amblard F; Zhou S; Liu P; Yoon J; Cox B; Muzzarelli K; Kuiper BD; Kovari LC; Schinazi RF
Bioorg Med Chem Lett; 2018 Jul; 28(12):2165-2170. PubMed ID: 29779977
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection.
Oo A; Rausalu K; Merits A; Higgs S; Vanlandingham D; Bakar SA; Zandi K
Antiviral Res; 2018 Feb; 150():101-111. PubMed ID: 29269135
[TBL] [Abstract][Full Text] [Related]
17. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.
Staveness D; Abdelnabi R; Schrier AJ; Loy BA; Verma VA; DeChristopher BA; Near KE; Neyts J; Delang L; Leyssen P; Wender PA
J Nat Prod; 2016 Apr; 79(4):675-9. PubMed ID: 26900625
[TBL] [Abstract][Full Text] [Related]
18. Bis(benzofuran-thiazolidinone)s and bis(benzofuran-thiazinanone)s as inhibiting agents for chikungunya virus.
Hwu JR; Gupta NK; Tsay SC; Huang WC; Albulescu IC; Kovacikova K; van Hemert MJ
Antiviral Res; 2017 Oct; 146():96-101. PubMed ID: 28830714
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of stearylamine against chikungunya virus.
Jeengar MK; Kurakula M; Patil P; More A; Sistla R; Parashar D
Chem Phys Lipids; 2021 Mar; 235():105049. PubMed ID: 33422549
[TBL] [Abstract][Full Text] [Related]
20. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
Rothan HA; Bahrani H; Abdulrahman AY; Mohamed Z; Teoh TC; Othman S; Rashid NN; Rahman NA; Yusof R
Antiviral Res; 2016 Mar; 127():50-6. PubMed ID: 26794398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
